Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience

INTRODUCTION: Tyrosine kinase inhibitor (TKI) therapy has greatly improved the prognosis of patients with chronic myeloid leukemia (CML), improving the survival expectancy of patients with chronic phase (CP) CML to that of the general population. However, despite these advances, nearly 50% of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Chitanava, Tamara, Matvienko, Iuliia, Shuvaev, Vasily, Voloshin, Sergey, Martynkevich, Irina, Vlasova, Yulia, Efremova, Elizaveta, Mileeva, Ekaterina, Pirkhalo, Anna, Makarova, Taiana, Vlasik, Roman, Karyagina, Elena, Il`ina, Natalia, Medvedeva, Nadezhda, Dorofeeva, Natalia, Shneider, Tatiana, Siordiya, Nadia, Kulemina, Olga, Sbityakova, Evgenia, Lazorko, Natalia, Alexeeva, Julia, Motorin, Dmitrii, Morozova, Elena, Lomaia, Elza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061114/
https://www.ncbi.nlm.nih.gov/pubmed/37007128
http://dx.doi.org/10.3389/fonc.2023.1138683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061114/
https://www.ncbi.nlm.nih.gov/pubmed/37007128
http://dx.doi.org/10.3389/fonc.2023.1138683

Ejemplares similares